Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gross Profit (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Gross Profit for 6 consecutive years, with $496000.0 as the latest value for Q4 2025.

  • Quarterly Gross Profit fell 16.64% to $496000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, up 212.16% year-over-year, with the annual reading at $2.3 million for FY2025, 210.54% up from the prior year.
  • Gross Profit hit $496000.0 in Q4 2025 for Insight Molecular Diagnostics, up from $139000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $2.6 million in Q4 2021 to a low of -$866000.0 in Q3 2021.
  • Historically, Gross Profit has averaged $243250.0 across 5 years, with a median of $64500.0 in 2021.
  • Biggest five-year swings in Gross Profit: tumbled 1782.61% in 2021 and later soared 2844.44% in 2025.
  • Year by year, Gross Profit stood at $2.6 million in 2021, then crashed by 101.04% to -$27000.0 in 2022, then crashed by 333.33% to -$117000.0 in 2023, then skyrocketed by 608.55% to $595000.0 in 2024, then fell by 16.64% to $496000.0 in 2025.
  • Business Quant data shows Gross Profit for IMDX at $496000.0 in Q4 2025, $139000.0 in Q3 2025, and $350000.0 in Q2 2025.